- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
FDA Advisers Urge Approval of First CCR5 Blocker for AIDS
SILVER SPRING, Md. -- An FDA advisory panel has unanimously recommended accelerated approval of a novel antiretroviral drug as an add-on treatment for adult infected with CCR5-tropic HIV-1.
SILVER SPRING, Md., April 27 -- An FDA advisory panel has unanimously recommended accelerated approval of a novel oral antiretroviral drug as an add-on treatment for adults infected with CCR5-tropic HIV-1.
Maraviroc, which is being developed by Pfizer and would be marketed as Celsentri, is the first in a new class of antiretroviral drugs called CCR5-receptor antagonists.
The FDA is expected to make a final decision on the drug within weeks. Although the FDA generally follows the recommendations of its advisory panels, it is not obligated to do so.
In clinical trials about 45% of patients randomized to maraviroc on top of standard antiretroviral therapy had undetectable HIV viral loads after 24 weeks, versus 23% of placebo patients.
The drug was given twice daily in 150- or 300-mg tablets. Unlike available AIDS drugs that attack HIV-infected cells, maraviroc blocks the virus from entering healthy immune cells.
An FDA briefing document noted that a "concern during clinical development has been the possibility of an increase in infection or malignancy with its use." Development of a second drug in the same class, aplaviroc, was halted when it was linked to hepatotoxicity in trials and a possible association with lymphoma has been reported for a third investigational agent-vicriviroc , which targets a different CCR5 co-receptor antagonist.
But the FDA's maraviroc review-team members reported that they saw no evidence of an increase in lymphoma or other cancers in the Pfizer data. They did, however, note a possible increase in cardiovascular events, but said it was not clear whether this was a true cardiovascular signal.
Likewise, there was no evidence of hepatoxicity, but there was a small increase in herpes and some other infections.
Although the FDA's Antiretroviral Products' Advisory Committee unanimously recommended approval, the committee said that since there are no long-term safety or efficacy data, the FDA should require close post-marketing surveillance.
